킴스온라인

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2026)

08 January - 10 January, 2026, United States

Adjuvant S-1 + oxaliplatin yields survival benefit in G/GEJ cancer

2026-03-04

Combining S-1 and oxaliplatin (SOX) as an adjuvant chemotherapy significantly improves overall survival (OS) and disease-free survival (DFS) compared with S-1 alone in patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, according to the final results of the CAPITAL trial presented at ASCO GI 2026.
GLP-1RA bests aspirin for CRC prevention

2026-03-04

Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) appears to confer greater protection against the development of colorectal cancer (CRC) as compared with aspirin, according to a retrospective study.
Physical activity, especially walking, relieves fatigue in CRC survivors

2026-03-04

A study presented at ASCO GI 2026 shows that colorectal cancer (CRC) survivors who remain physically active, particularly through walking, are less likely to experience severe fatigue and more likely to report better quality of life (QoL).
COMMIT: Triplet regimen extends PFS in select CRC patients

2026-03-04

In the phase III COMMIT* trial, a combination of mFOLFOX6 (FFX), atezolizumab, and bevacizumab significantly improves progression-free survival (PFS) in patients with deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer (dMMR/MSI-H mCRC).
Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

2026-03-04

Treatment with zanidatamab combined with tislelizumab and/or chemotherapy (CT) significantly improves progression-free survival (PFS) in patients with HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA), as shown in the primary analysis from HERIZON-GEA-01.

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

주요메뉴

최근 본 콘텐츠